A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a
screening, a dosing and a follow-up visit.
Dosing at visit 2, of MKC253 Inhalation Powder, Glucagon-Like Peptide-1 (GLP-1) will be given
at 5 dose levels.